Morgan Stanley reiterated coverage on Bioventus with a new price target

3/11/22 8:45:27 AM ET

Medical/Dental Instruments

Health Care

Morgan Stanley reiterated coverage of Bioventus with a rating of Overweight and set a new price target of $18.00 from $20.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BVS

Date	Price Target	Rating	Analyst
12/17/2024	$12.00 → $13.00	Underweight → Neutral	Analyst
12/7/2023	$7.00	Hold → Buy	Canaccord Genuity
8/9/2023	$4.00 → $6.00	Hold → Buy	Craig Hallum
11/22/2022		Buy → Hold	Craig Hallum
11/9/2022	$18.00 → $6.00	Buy → Hold	Canaccord Genuity
11/9/2022		Overweight → Underweight	JP Morgan
3/15/2022	$30.00	Buy	Craig Hallum
3/11/2022	$20.00 → $18.00	Overweight	Morgan Stanley